المؤلفون: Abdul Rahman Jazieh, Hakan Akbulut, Giuseppe Curigliano, Alvaro Rogado, Abdullah Ali Alsharm, Evangelia D. Razis, Layth Mula-Hussain, Hassan Errihani, Adnan Khattak, Roselle B. De Guzman, Clarissa Mathias, Mohammad Omar Farouq Alkaiyat, Hoda Jradi, Christian Rolfo

المصدر: JCO Global Oncology, Vol , Iss 6, Pp 1428-1438 (2020)

مصطلحات موضوعية: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: PURPOSEThe COVID-19 pandemic affected health care systems globally and resulted in the interruption of usual care in many health care facilities, exposing vulnerable patients with cancer to significant risks. Our study aimed to evaluate the impact of this pandemic on cancer care worldwide.METHODSWe conducted a cross-sectional study using a validated web-based questionnaire of 51 items. The questionnaire obtained information on the capacity and services offered at these centers, magnitude of disruption of care, reasons for disruption, challenges faced, interventions implemented, and the estimation of patient harm during the pandemic.RESULTSA total of 356 centers from 54 countries across six continents participated between April 21 and May 8, 2020. These centers serve 716,979 new patients with cancer a year. Most of them (88.2%) reported facing challenges in delivering care during the pandemic. Although 55.34% reduced services as part of a preemptive strategy, other common reasons included an overwhelmed system (19.94%), lack of personal protective equipment (19.10%), staff shortage (17.98%), and restricted access to medications (9.83%). Missing at least one cycle of therapy by > 10% of patients was reported in 46.31% of the centers. Participants reported patient exposure to harm from interruption of cancer-specific care (36.52%) and noncancer-related care (39.04%), with some centers estimating that up to 80% of their patients were exposed to harm.CONCLUSIONThe detrimental impact of the COVID-19 pandemic on cancer care is widespread, with varying magnitude among centers worldwide. Additional research to assess this impact at the patient level is required.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2687-8941Test

الوصول الحر: https://doaj.org/article/8a39d24e21604f5997a57b98f6b89dbfTest

المؤلفون: Abdullah Ali Alsharm, Ahood Sayed, Mohammad Azhar Aziz, Abdulhadi samman, Jahad Alghamdi, Alhanouf Alomani, Faisal Almajed, Bader Almuzzaini, Abdulmohsen G Ahejaily, Saeed Alshieban, Mohamed Al Balwi, Manal Abudawood, Saleh Al-Ghamdi, Fida Aljasser

المصدر: Journal of Personalized Medicine, Vol 11, Iss 535, p 535 (2021)
Journal of Personalized Medicine
Volume 11
Issue 6

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Colorectal cancer, Medicine (miscellaneous), colorectal cancer, Computational biology, Biology, Gene mutation, Article, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Biomarker discovery, Gene, 030304 developmental biology, AmpliSeq, 0303 health sciences, business.industry, allergology, Cancer, personalized medicine, medicine.disease, 030220 oncology & carcinogenesis, biomarker, Medicine, Biomarker (medicine), Identification (biology), Personalized medicine, business

الوصف: Biomarker discovery would be an important tool in advancing and utilizing the concept of precision and personalized medicine in the clinic. Discovery of novel variants in local population provides confident targets for developing biomarkers for personalized medicine. We identified the need to generate high-quality sequencing data from local colorectal cancer patients and understand the pattern of occurrence of variants. In this report, we used archived samples from Saudi Arabia and used the AmpliSeq comprehensive cancer panel to identify novel somatic variants. We report a comprehensive analysis of next-generation sequencing results with a coverage of >
300X. We identified 466 novel variants which were previously unreported in COSMIC and ICGC databases. We analyzed the genes associated with these variants in terms of their frequency of occurrence, probable pathogenicity, and clinicopathological features. Among pathogenic somatic variants, 174 were identified for the first time in the large intestine. APC, RET, and EGFR genes were most frequently mutated. A higher number of variants were identified in the left colon. Occurrence of variants in ERBB2 was significantly correlated with those of EGFR and ATR genes. Network analyses of the identified genes provide functional perspective of the identified genes and suggest affected pathways and probable biomarker candidates. This report lays the ground work for biomarker discovery and identification of driver gene mutations in local population.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f97ccae2e71e998feae607d4ebc7c1cTest
https://doi.org/10.3390/jpm11060535Test